
Aarey Drugs Analyst Review 2027: A Stock That Doubled on a Business Earning ₹1.37 Crore a Quarter
Updated: 17 Nov 2026 • 2:11 pm
Posted by:

Aarey Drugs & Pharmaceuticals Stock Snapshot (16 Nov 2026 close)
- Current Market Price (CMP): ₹111.12
- 52-Week High / Low: ₹116.80 / ₹50.31
- Market Capitalisation: ₹351 crore
- P/E Ratio vs Industry P/E: 84.1 vs 52.2
- Latest Quarter (Q2 FY27) Revenue: ₹88.62 crore (net sales)
- Latest Quarter (Q2 FY27) Net Profit: ₹1.37 crore
Quick Answer: The Aarey Drugs analyst review 2027 has to begin with a plain fact: no brokerage publishes a rating or target on this micro-cap, so there is no Aarey Drugs share price target 2027 from analysts to cite. What the numbers show is a stock that has risen about 121% from its 52-week low of ₹50.31 to ₹111.12, while Q2 FY27 net sales were ₹88.62 crore and profit was ₹1.37 crore. Operating margin was only about 2.4%, and most of pre-tax profit came from other income. At a P/E near 84, the valuation already assumes a big improvement.
The Aarey Drugs analyst review 2027 is a study in how far a share price can move ahead of the business underneath it. Anyone searching for an Aarey Drugs share price target 2027 should know that no research house covers the stock. The useful exercise is to read the company's own numbers and judge them against the rally.
Aarey Drugs & Pharmaceuticals closed at ₹111.12 on 16 November 2026, about 5% below its 52-week high of ₹116.80 and more than double its low of ₹50.31. This Aarey Drugs analyst review 2027 covers the latest results, how the company earns, its balance sheet, ownership changes and what will shape the Aarey Drugs stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the Aarey Drugs Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| No verified coverage | Not available | Not available | As of November 2026 |
We could not find a single dated, named brokerage report on Aarey Drugs. That is common for companies with a market value near ₹350 crore and little institutional ownership. It also means price moves are driven by traders and retail buyers rather than by research estimates.
Without targets, this Aarey Drugs analyst review 2027 relies on reported results, valuation ratios and shareholding data. Any figure presented elsewhere as an Aarey Drugs share price target 2027 from analysts should be treated with caution unless it names a registered research firm and a date.
Q2 FY27 Results in the Aarey Drugs Analyst Review 2027
| Quarter | Net Sales | Net Profit | Operating Margin |
|---|---|---|---|
| Sep 2026 (Q2 FY27) | ₹88.62 crore | ₹1.37 crore | 2.40% |
| Jun 2026 (Q1 FY27) | ₹44.63 crore | ₹1.02 crore | 2.98% |
| Mar 2026 (Q4 FY26) | ₹189.47 crore | ₹1.56 crore | 2.29% |
| Dec 2025 (Q3 FY26) | ₹96.43 crore | ₹0.57 crore | -1.57% |
| Sep 2025 (Q2 FY26) | ₹84.16 crore | ₹1.02 crore | 3.14% |
Sales rose about 5% from a year earlier and almost doubled from a weak June quarter. Profit of ₹1.37 crore was up about 34% from both the June quarter and the year-ago quarter. Those percentages sound strong, but the absolute numbers are small for a ₹351 crore company.
Two features of the Aarey Drugs analyst review 2027 numbers stand out. First, revenue swings sharply from quarter to quarter, from ₹44.63 crore to ₹189.47 crore within the last year. Second, operating margins sit between roughly 2% and 3%, and other income made up about 97.6% of pre-tax profit in Q2. In other words, the core business barely earns more than its costs, and the reported profit depends on non-operating income. First-half sales were also about 28.5% lower than a year earlier.
How Aarey Drugs Makes Money
Incorporated in 1990 and based in Mumbai, Aarey Drugs & Pharmaceuticals makes active pharmaceutical ingredients, also called bulk drugs, and supplies chemical products for industrial uses. Its income depends on:
- Bulk drug volumes: orders from formulation companies that turn APIs into finished medicines.
- Raw material spreads: the gap between input chemical prices and selling prices.
- Trading activity: the large swings in quarterly sales suggest a meaningful trading or order-based component, though the company does not split this out in the data we reviewed.
Low margins are typical for small API suppliers without patented or specialised products. The Aarey Drugs analyst review 2027 question is whether the company can move into higher-value products.
Growth Triggers in the Aarey Drugs Analyst Review 2027
- Fresh capital: on 30 September 2026 the company allotted 11.5 lakh shares on conversion of warrants, raising paid-up capital to ₹31.87 crore. New money can fund capacity or working capital.
- Revenue scale: FY25 revenue was about ₹474 crore, so the business can generate large sales when orders arrive.
- Sector support: government incentives for domestic API production aim to reduce India's import dependence, which helps local bulk drug makers.
- Institutional interest: domestic institutions held 1.44% in September 2026 against nil in December 2025.
Key Risks in the Aarey Drugs Analyst Review 2027
- Thin core margins: an operating margin near 2.4% leaves almost no buffer against raw material cost increases.
- Dependence on other income: about 97.6% of Q2 pre-tax profit came from non-operating sources.
- Valuation: a P/E of about 84 compares with an industry figure near 52, despite low returns.
- Low returns: return on equity is about 2.6%.
- Volatile sales: large quarterly swings make earnings hard to predict.
- No research coverage: without analyst scrutiny, price discovery can be erratic in both directions.
Compare Aarey Drugs With Small-Cap Pharma Peers on the Univest Screener
Aarey Drugs Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (16 Nov 2026 close) | ₹111.12 |
| 52-Week High / Low | ₹116.80 / ₹50.31 |
| Market Capitalisation | ₹351 crore |
| P/E (TTM) vs Industry | 84.1 vs 52.2 |
| Price to Book | 2.07 |
| Book Value per Share | ₹53.28 |
| Return on Equity | 2.64% |
| Debt to Equity | 0.33 |
| FY26 Net Profit | ₹3.97 crore |
The price to book value of about 2.1 is not extreme on its own. The concern in this Aarey Drugs analyst review 2027 is the combination of a high P/E with a very low return on equity, which means investors are paying for profits that have not yet appeared.
Shareholding Trend
| Holder | Dec 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 39.05% | 41.45% | +2.40 pts |
| Foreign Investors (FII) | 3.86% | 4.27% | +0.41 pts |
| Domestic Institutions (DII) | 0.00% | 1.44% | +1.44 pts |
| Public | 57.09% | 52.83% | -4.26 pts |
The promoter Ghatalia family raised its stake to 41.45%, consistent with the warrant conversion. Public holding fell by more than four points, and small institutional stakes appeared for the first time. With public shareholders still owning more than half the company, retail sentiment carries a lot of weight in the Aarey Drugs analyst review 2027.
What to Watch After the Aarey Drugs Analyst Review 2027
- Operating margin: any sustained move above 3% would be the first sign of real improvement.
- Use of warrant money: whether the new capital goes into capacity or higher-value products.
- Other income share: a falling share of non-operating income in profit would improve earnings quality.
- Q3 FY27 sales: whether revenue stays near ₹90 crore or swings again.
- Any research initiation: the first named brokerage note would create a real Aarey Drugs share price target 2027 benchmark.
Final Word on the Aarey Drugs Analyst Review 2027
The Aarey Drugs analyst review 2027 finds a micro-cap whose share price has more than doubled while its business continues to earn thin margins. Q2 FY27 profit of ₹1.37 crore was higher than a year ago, but it relied heavily on other income, and sales remain volatile.
With no brokerage coverage, a P/E near 84 and return on equity below 3%, the Aarey Drugs stock outlook 2027 depends on visible progress in core profitability. Investors should treat this as a higher-risk stock and verify any claims carefully. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Aarey Drugs analyst review 2027 show?
It shows no brokerage coverage and a stock that has risen about 121% from its 52-week low of ₹50.31. Q2 FY27 net sales were ₹88.62 crore and profit was ₹1.37 crore. Operating margin was only about 2.4%.
Is there an Aarey Drugs share price target 2027 from brokerages?
No verified brokerage target exists for Aarey Drugs as of November 2026. We found no dated report from a named research firm. Investors should be wary of targets that do not name a registered research house.
How profitable is the business in the Aarey Drugs analyst review 2027?
Operating margins have ranged from about -1.6% to 3.1% over the last five quarters. In Q2 FY27, about 97.6% of pre-tax profit came from other income. Return on equity is about 2.6%.
Why does Aarey Drugs revenue swing so much?
Quarterly sales moved from ₹44.63 crore in June 2026 to ₹189.47 crore in March 2026 within a year. The pattern suggests order-based or trading-linked sales. First-half FY27 sales were about 28.5% lower than a year earlier.
Is Aarey Drugs expensive, based on the Aarey Drugs analyst review 2027?
The stock trades at a P/E of about 84.1, above the industry figure of about 52.2. Its price to book is 2.07 on a book value of ₹53.28 per share. The high P/E combined with low returns means the valuation assumes a large improvement in earnings.
What changed in shareholding during the Aarey Drugs analyst review 2027 period?
Promoter holding rose to 41.45% in September 2026 from 39.05% in December 2025, in line with a warrant conversion of 11.5 lakh shares. Domestic institutions took a 1.44% stake. Public holding fell to 52.83%.
What should investors track after the Aarey Drugs analyst review 2027?
Watch whether operating margin rises above 3% and whether other income stops dominating profit. Track how the warrant money is used. The first named brokerage report, if one appears, would give a real benchmark for valuation.
Recent Articles

Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry's
17 November 2026

Aakash Exploration Services Analyst Review 2027: Sales Up 9% but a Q2 Loss. Can This ₹8 Oilfield Stock Recover?
17 November 2026

AAA Technologies Analyst Review 2027: New Owners, a ₹101 Open Offer and a Stock Now Below It
17 November 2026

A2Z Infra Engineering Analyst Review 2027: Revenue Down 31%, Stock Near Its Low and an Auditor Warning
17 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry's
Aakash Exploration Services Analyst Review 2027: Sales Up 9% but a Q2 Loss. Can This ₹8 Oilfield Stock Recover?
AAA Technologies Analyst Review 2027: New Owners, a ₹101 Open Offer and a Stock Now Below It
A2Z Infra Engineering Analyst Review 2027: Revenue Down 31%, Stock Near Its Low and an Auditor Warning
63 moons technologies Analyst Review 2027: Cyber Arm Lifts Guidance to ₹600 Crore, But the Group Still Loses Money
Popular this week
5Paisa Capital Analyst Review 2027: Revenue Up 12%, Profit Down 26% and an MTF Book Growing 32%

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





